Alnylam
Pharmaceuticals ALNY announced today that it has presented new pre-clinical data
with ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) in
…
Alnylam
Pharmaceuticals (NASDAQ: ALNY announced today that it has presented new pre-clinical data
with ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) in
development for the treatment of liver disease associated with
AAT deficiency. These data
were presented in a poster entitled “Developing an RNAi Therapeutic for
Liver Disease Associated with Alpha-1-Antitrypsin Deficiency” at the 64th
Annual Meeting of the American Association for the Study of Liver
Diseases (AASLD, “The Liver Meeting”) held November 1 – 5, 2013 in
Washington, D.C. AAT deficiency liver disease is a rare genetic
disorder, with the most common mutation being in the “Z-allele,” which
results in the accumulation of the mutant AAT protein (Z-AAT)
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in